HighTide Therapeutics Inc (HKSE:02511) Share Price

Company Profile

Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Building D, Guangdong
Floor 9 to 10, Fubao Community, Futian District
Shenzhen-Hong Kong Science and
Technology Innovation Cooperation Zone
Shenzhen518112
CHN
T: +86 75526626253
https://www.hightidetx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70

Recommended

Shares soared 30% in the last week but are still undervalued.

Shane Ponraj, CFA | 11 August 2025

In exchange for an export license to China the chip makers will pay the US government 15% of revenue.

Brian Colello, CPA | 11 August 2025

Shares of Berkshire have plunged more than 12% since May.

Sarah Hansen | 11 August 2025

Index	Last price	Change	% Change
All Ordinaries	9,117.60	41.00	0.45%
CAC 40	7,698.52	44.48	-0.57%
DAX 40	24,081.34	81.52	-0.34%
Dow JONES (US)	43,975.09	200.52	-0.45%
FTSE 100	9,129.71	33.98	0.37%
HKSE	24,906.81	47.99	0.19%
NASDAQ	21,385.40	64.62	-0.30%
Nikkei 225	41,820.48	761.33	1.85%
NZX 50 Index	12,911.86	67.23	0.52%
S&P 500	6,373.45	16.00	-0.25%
S&P/ASX 200	8,844.80	37.70	0.43%
SSE Composite Index	3,647.55	12.42	0.34%